

(19) World Intellectual Property  
Organization  
International Bureau



(43) International Publication Date  
28 October 2004 (28.10.2004)

PCT

(10) International Publication Number  
**WO 2004/092192 A1**

(51) International Patent Classification<sup>7</sup>: **C07H 11/00**,  
13/06, 17/04, A61K 31/7024, A61P 31/06

(21) International Application Number:  
PCT/EP2004/003830

(22) International Filing Date: 9 April 2004 (09.04.2004)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:  
03290965.7 18 April 2003 (18.04.2003) EP

(71) Applicant (for all designated States except US): **CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE** [FR/FR]; 3, rue Michel-Ange, F-75794 Paris Cedex 16 (FR).

(72) Inventors; and

(75) Inventors/Applicants (for US only): **PUZO, Germain** [FR/FR]; 2, impasse Goudouli, F-31320 Auzeville Tolosane (FR). **GILLERON, Martine** [FR/FR]; 56, chemin del Prat, F-31320 Auzeville Tolosane (FR). **STENGER, Steffen** [DE/DE]; Hugentottenplatz 1, 91054 Erlanger (DE). **DE LIBERO, Gennaro** [IT/CH]; Peter Ochs Strasse 7, CH-4059 Basel (CH).

(74) Agents: **GROSSET-FOURNIER, Chantal** et al.; Grosset-Fournier & Demachy Sàrl, 54, rue Saint-Lazare, F-75009 Paris (FR).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.


(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

**Published:**

- with international search report
- before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: SULFOGLYCOLIPID ANTIGENS, THEIR EXTRACTION FROM MYCOBACTERIUM TUBERCULOSIS, AND THEIR USE AGAINST TUBERCULOSIS



(57) Abstract: The present invention relates to compounds of the following general formula: (I) wherein R<sub>1</sub> and R<sub>2</sub> are fatty acyl groups, a process to extract them from *Mycobacterium tuberculosis*, and their use in the treatment or the prophylaxis of tuberculosis.

**THIS PAGE BLANK (USPTO)**


# SULFOGLYCOLIPID ANTIGENS, THEIR EXTRACTION FROM MYCOBACTERIUM TUBERCULOSIS, AND THEIR USE AGAINST TUBERCULOSIS

5

The present invention relates to new sulfolglycolipid antigens, a process to extract them from *Mycobacterium tuberculosis*, and their use in the treatment or the prophylaxis of tuberculosis.


Each year, tuberculosis is the estimated cause of 3 million deaths. The causative agent of this disease is a bacterium, *Mycobacterium tuberculosis*, by which one of every three people is infected worldwide. It is transmitted through the air by sneezes or coughs of infected persons. The bacterium may be harboured in an inactive state by infected persons who will never develop the disease. However, under certain conditions, such as age or depression of the immune system, the bacterium may become active and cause the onset of tuberculosis.

It seems that the mycobacterial envelope accounts for an important part of the virulence of bacteria of the *Mycobacterium* genus. Indeed, up to 40% of mycobacteria dry weight is constituted by lipids. Among those lipids, some of them seem restricted to *Mycobacterium tuberculosis*, such as sulfolglycolipids for instance (Vergne I. and Daffe M. *Frontiers in Bioscience* (1998) 3:865-876). This family of glycolipids is typified by a sulfate substituent on position 2' of a trehalose unit (*i.e.*  $\alpha$ -D-glucopyranosyl-(1-1')- $\alpha$ '-D-glucopyranoside) (A).



A

Members of the family differ from one another by the number, the position and the type of fatty acids substituted on the trehalose units. The fatty acids substituents notably comprise palmitic acid, stearic acid, phthioceranoic acid and hydroxyphthioceranoic acid. The latter two fatty acids are characteristic of sulfolglycolipids. The most abundant sulfolglycolipid is SL-I (Goren *et al. Biochemistry* (1976) 15:2728-2735) (B).



Its abundance has been shown to be correlated to strain virulence and it has been demonstrated that SL-I was able to inhibit macrophage antimicrobial activity and to block the effects of several inflammatory agents such as LPS, IFN- $\gamma$  or TNF- $\alpha$  on macrophages (Vergne I. and Daffe M. *Frontiers in Bioscience* (1998) 3:865-876).

At present, there are two ways of fighting tuberculosis: antibiotic therapy and vaccination.

The vaccine used for the prophylaxis of tuberculosis consists of a live attenuated bacterium of the *Mycobacterium bovis* species. It is named BCG, Bacillus of Calmette and Guerin, after the two scientists who first devised it, at the beginning of the 20<sup>th</sup> century. In addition to its flaw as being a live vaccine, which precludes its use in immunodepressed patients, its protection against tuberculosis is controversial. Thus, BCG protective efficacy in adults range from 0% to 80% according to varying studies, besides, it fails to protect against pulmonary tuberculosis, the most prevalent disease form in adults.


Moreover, antibiotic resistant strains of *M. tuberculosis* have been found in over 35 countries.

Hence, it is a subject of the present invention to provide a more effective way of treating and/or preventing tuberculosis.

It is a further subject of the invention to provide new immunogenic glycolipids extracted from *Mycobacterium tuberculosis*.

The invention notably provides new sulfoglycolipid antigens, specific of *M. tuberculosis*, which have been shown to stimulate CD1-restricted T lymphocytes *in vitro*.

The invention relates to compounds of the following general formula (I):




I

wherein  $R_1$  and  $R_2$  are fatty acyl groups.


Fatty acyl groups are derived from fatty acid groups which have been esterified to the hydroxyl groups in position 2 and 3 of the trehalose-2'-sulfate unit.

Fatty acid groups are aliphatic carboxylic acids which can be linear or ramified, saturated or unsaturated, unsubstituted or substituted by groups such as hydroxyl, or ketone.

The invention particularly relates to compounds of formula I, wherein  $R_1$  and  $R_2$  independently from each other represent a fatty acyl group containing from 16 to 60 carbon atoms, and more particularly wherein  $R_1$  and  $R_2$  are selected from the group comprising:



wherein  $m$  is 14 or 16 and  $n$  is an integer from 2 to 10,




wherein m is 14 or 16 and n is an integer from 2 to 10,

The fatty acyl groups notably comprise linear and saturated fatty acyl groups such as groups according to formula  $\text{---OC---(CH}_2\text{)}_k\text{---CH}_3$  wherein k is an integer from 14 to 58.

The invention more particularly relates to compounds of formula I, wherein  $R_1$  and  $R_2$  are selected from the group comprising palmitic acyl and stearic acyl, namely compounds of

5 following formulae:




The invention further relates to compounds of formula I, wherein at least one of  $R_1$  and  $R_2$  represents a hydroxyphthioceranoic acyl group.

10 The invention more specifically relates to compounds of formula I, wherein  $R_1$  or  $R_2$  represents a hydroxyphthioceranoic acyl group.

The invention more particularly relates to compounds of formula I, wherein:


- $R_1$  represents a hydroxyphthioceranoic acyl group, and  $R_2$  represents a palmitic acyl group or a stearic acyl group, namely compounds of following formula (II):



## II

wherein p is 14 or 16, m is 14 or 16 and n is an integer from 2 to 10, or

- R<sub>2</sub> represents a hydroxyphthioceranoic acyl group, and R<sub>1</sub> represents a palmitic acyl group or a stearic acyl group, namely compounds of following formula (III):



## III

wherein p is 14 or 16, m is 14 or 16 and n is an integer from 2 to 10.

The invention relates in particular to compounds of formula II, wherein:

- |    |   |
|----|---|
| 10 | - n = 2, m = 14 and p = 14      (II.1) ;  |
|    | - n = 2, m = 14 and p = 16      (II.2) ;  |
|    | - n = 2, m = 16 and p = 14      (II.3) ;  |
|    | - n = 2, m = 16 and p = 16      (II.4) ;  |
|    | - n = 3, m = 14 and p = 14      (II.5) ;  |
| 15 | - n = 3, m = 14 and p = 16      (II.6) ;  |
|    | - n = 3, m = 16 and p = 14      (II.7) ;  |
|    | - n = 3, m = 16 and p = 16      (II.8) ;  |
|    | - n = 4, m = 14 and p = 14      (II.9) ;  |
|    | - n = 4, m = 14 and p = 16      (II.10) ; |
| 20 | - n = 4, m = 16 and p = 14      (II.11) ; |
|    | - n = 4, m = 16 and p = 16      (II.12) ; |
|    | - n = 5, m = 14 and p = 14      (II.13) ; |
|    | - n = 5, m = 14 and p = 16      (II.14) ; |

- $n = 5, m = 16$  and  $p = 14$  (II.15);
- $n = 5, m = 16$  and  $p = 16$  (II.16);
- $n = 6, m = 14$  and  $p = 14$  (II.17);
- $n = 6, m = 14$  and  $p = 16$  (II.18);
- 5 -  $n = 6, m = 16$  and  $p = 14$  (II.19);
- $n = 6, m = 16$  and  $p = 16$  (II.20);
- $n = 7, m = 14$  and  $p = 14$  (II.21);
- $n = 7, m = 14$  and  $p = 16$  (II.22);
- $n = 7, m = 16$  and  $p = 14$  (II.23);
- 10 -  $n = 7, m = 16$  and  $p = 16$  (II.24);
- $n = 8, m = 14$  and  $p = 14$  (II.25);
- $n = 8, m = 14$  and  $p = 16$  (II.26);
- $n = 8, m = 16$  and  $p = 14$  (II.27);
- $n = 8, m = 16$  and  $p = 16$  (II.28);
- 15 -  $n = 9, m = 14$  and  $p = 14$  (II.29);
- $n = 9, m = 14$  and  $p = 16$  (II.30);
- $n = 9, m = 16$  and  $p = 14$  (II.31);
- $n = 9, m = 16$  and  $p = 16$  (II.32);
- $n = 10, m = 14$  and  $p = 14$  (II.33);
- 20 -  $n = 10, m = 14$  and  $p = 16$  (II.34);
- $n = 10, m = 16$  and  $p = 14$  (II.35);
- $n = 10, m = 16$  and  $p = 16$  (II.36);


or of formula III, wherein:

- $n = 2, m = 14$  and  $p = 14$  (III.1);
- 25 -  $n = 2, m = 14$  and  $p = 16$  (III.2);
- $n = 2, m = 16$  and  $p = 14$  (III.3);
- $n = 2, m = 16$  and  $p = 16$  (III.4);
- $n = 3, m = 14$  and  $p = 14$  (III.5);
- $n = 3, m = 14$  and  $p = 16$  (III.6);
- 30 -  $n = 3, m = 16$  and  $p = 14$  (III.7);
- $n = 3, m = 16$  and  $p = 16$  (III.8);
- $n = 4, m = 14$  and  $p = 14$  (III.9);
- $n = 4, m = 14$  and  $p = 16$  (III.10);
- $n = 4, m = 16$  and  $p = 14$  (III.11);




- $n = 4, m = 16$  and  $p = 16$  (III.12);
- $n = 5, m = 14$  and  $p = 14$  (III.13);
- $n = 5, m = 14$  and  $p = 16$  (III.14);
- $n = 5, m = 16$  and  $p = 14$  (III.15);
- 5 -  $n = 5, m = 16$  and  $p = 16$  (III.16);
- $n = 6, m = 14$  and  $p = 14$  (III.17);
- $n = 6, m = 14$  and  $p = 16$  (III.18);
- $n = 6, m = 16$  and  $p = 14$  (III.19);
- $n = 6, m = 16$  and  $p = 16$  (III.20);
- 10 -  $n = 7, m = 14$  and  $p = 14$  (III.21);
- $n = 7, m = 14$  and  $p = 16$  (III.22);
- $n = 7, m = 16$  and  $p = 14$  (III.23);
- $n = 7, m = 16$  and  $p = 16$  (III.24);
- $n = 8, m = 14$  and  $p = 14$  (III.25);
- 15 -  $n = 8, m = 14$  and  $p = 16$  (III.26);
- $n = 8, m = 16$  and  $p = 14$  (III.27);
- $n = 8, m = 16$  and  $p = 16$  (III.28);
- $n = 9, m = 14$  and  $p = 14$  (III.29);
- $n = 9, m = 14$  and  $p = 16$  (III.30);
- 20 -  $n = 9, m = 16$  and  $p = 14$  (III.31);
- $n = 9, m = 16$  and  $p = 16$  (III.32);
- $n = 10, m = 14$  and  $p = 14$  (III.33);
- $n = 10, m = 14$  and  $p = 16$  (III.34);
- $n = 10, m = 16$  and  $p = 14$  (III.35);
- 25 -  $n = 10, m = 16$  and  $p = 16$  (III.36);


The invention more specifically relates to compounds of following formulae:



III.21




II.21




III.22

5




**И.22**

10



III.23



II.23

In a preferred embodiment, the invention relates to compounds of formulae III-21, III-22 or III-23.

According to another embodiment, the invention relates to a composition comprising at least two different compounds of formula I such as defined above.

The invention further relates to a composition characterized in that it comprises a mixture of compounds selected from the compounds of formulae II and III, preferably those of formulae II-1 to II-36 and of formulae III-1 to III-36, and more preferably those of formulae II-21, II-22, II-23, III-21, III-22 and III-23.

The invention also relates to a composition comprising a mixture of compounds selected from the compounds of formula III, preferably those of formulae III-1 to III-36, and more preferably those of formulae III-21, III-22 and III-23.

The invention relates in particular to a composition as defined above, wherein compounds selected from the compounds of formulae II-21, II-22, II-23, III-21, III-22 and III-23 represent from about 20% to about 100%, more particularly about 30%, of the total amount of compounds of formula I of said composition.

The invention also relates to a composition as defined above, wherein compounds selected from the compounds of formulae III-21, III-22 and III-23 represent from about 20% to about 100%, more particularly about 30%, of the total amount of compounds of formula I of said composition.

The invention notably relates to a composition as defined above, wherein at least one compound, selected from the list consisting of compounds of formulae II-21, II-22, II-23, III-21, III-22 and III-23, represents from about 20% to about 100%, notably 30% of the total amount of compounds of formula I of said composition.

The percentage used to characterize the contents of the above described compositions is a molar percentage.

The invention also relates to a pharmaceutical composition comprising at least one compound as defined above, or a composition as defined above, in association with a pharmaceutically acceptable vehicle.

A pharmaceutically acceptable carrier comprises in particular liposomes.

5 The composition may also comprise vaccine adjuvants. Vaccine adjuvants for use in human individuals or animals are well known to the man skilled in the art, a list of such salts can be found for instance in "A compendium of vaccine adjuvants and excipients" 2<sup>nd</sup> edition, Vogel *et al.* Particular vaccine adjuvants notably comprise aluminum salts or M59, for example.

10 The invention particularly relates to a pharmaceutical composition as defined above, characterized in that it is presented in a form intended for administration by oral or injectable route.

The invention more particularly relates to a pharmaceutical composition as defined above, characterized in that it comprises one or more other products useful for the treatment or the  
15 prophylaxis of tuberculosis, such as BCG or mycobacterial proteins.

BCG stands for Bacillus of Calmette and Guérin, the different strains of BCG currently used for vaccination are notably described in Behr M.A. *et al. Science* (1999) 284:1520-1523.

The expression "mycobacterial proteins" refers to proteins, or fragments thereof, which are encoded by the genome of bacteria of the *Mycobacterium* genus and notably by the  
20 genome of *Mycobacterium tuberculosis*, such proteins may be advantageously recombinant. According to a preferred embodiment said mycobacterial proteins are antigens of *M. tuberculosis*.

Other products useful for the treatment or the prophylaxis of tuberculosis notably comprise immunomodulators, such as cytokines, DNA fragments encoding *M. tuberculosis*  
25 antigens, live *M. tuberculosis* deletion mutants, such as mutants in which virulence genes have been deleted, or live recombinant BCG, such as BCG expressing antigens of *M. tuberculosis*.

As used herein, tuberculosis refers to the disease caused in humans by the bacterium *Mycobacterium tuberculosis*, but also to the corresponding disease in animals.

30 According to another embodiment, the invention relates to products comprising:

- at least one compound as defined above,
- and at least one other product useful for the treatment or the prophylaxis of tuberculosis, such as BCG or mycobacterial proteins,

as a combined preparation for simultaneous, separate or sequential use in the treatment or the prophylaxis of tuberculosis.

The invention also relates to the use of at least one compound as defined above, or of an above mentioned composition, for the preparation of a medicament, notably a vaccine,  
5 intended for the treatment or the prophylaxis of tuberculosis.

Optionally the vaccine may comprise a vaccine adjuvant such as described above.

The invention relates to the use of at least one compound as defined above, or of a composition according as defined above, as an immune reaction activator, and more particularly an inflammatory reaction activator.

10 By "immune reaction activator" is meant a compound which has the ability to activate components or processes of the immune reaction, *in vitro* or *in vivo*, in particular cells of the immune system, such as T lymphocytes, B lymphocytes, antigen presenting cells (APCs), such as dendritic cells or macrophages, monocytes or granulocytes.

By "inflammatory reaction activator" is meant a compound which has the ability to  
15 activate components or processes of the inflammatory reaction, *in vitro* or *in vivo*, such as diapedesis, capillary permeabilization, macrophage activation or fever onset for instance.

The invention also relates to the use of at least one compound as defined above, or of a composition as defined above, to induce the activation of T lymphocytes, notably CD1-restricted T lymphocytes. The activation can proceed *in vitro* or *in vivo*.

20 The activation of T lymphocytes can be assessed by several methods, such as measuring cell multiplication or cytokine production such as IFN- $\gamma$  (interferon- $\gamma$ ), IL-2 (interleukine-2), IL-4 (interleukine-4), or TNF- $\alpha$  (tumor necrosis factor  $\alpha$ ), for instance.

CD1-restricted T lymphocytes are T lymphocytes which are activated by antigens presented by CD1 molecules.

25 The invention also relates to the use of at least one compound as defined above, or of a composition as defined above, to induce the production of IFN- $\gamma$ , TNF- $\alpha$ , IL-4 or granulysin.

This production induction can be done *in vitro* or *in vivo*. The production of IFN- $\gamma$ , TNF- $\alpha$ , IL-4 or granulysin can be measured for instance by immunoassays, such as ELISA (enzyme linked immunosorbent assay) or EIA (enzyme immunoassay).

30 According to another embodiment, the invention relates to a process for generating T cell clones, characterized in that it comprises the following stages:

- incubating antigen presenting cells (APCs), notably dendritic cells, with a *Mycobacterium tuberculosis* envelope preparation substantially devoid of proteins, to obtain non-protein envelope antigen loaded APCs,

- contacting peripheral blood mononuclear cells with the envelope antigen loaded APCs to obtain proliferating T cells,
  - cloning proliferating T cells by limiting dilution and selecting the clones releasing a molecule selected from the group comprising IFN- $\gamma$ , TNF- $\alpha$ , granulysin or IL-4
- 5 when contacted by envelope antigen loaded APCs to obtain T cell clones.

The invention further relates to T cell clones such as obtained by the abovementioned process. Such a T cell clone is described in the examples as Z4B27.

According to another embodiment, the invention relates to a process for screening products, such as sulfoglycolipids extracted from *Mycobacterium tuberculosis*, characterized

10 in that it comprises the following stages:

- contacting dendritic cells loaded with the product to screen, notably sulfoglycolipids extracted from *Mycobacterium tuberculosis*, with the above-defined T cell clones,
  - detecting a molecule selected from the group comprising IFN- $\gamma$ , TNF- $\alpha$ ,
- 15 granulysin or IL-4, released by the T cell clones.

The invention also relates to a process for the extraction of compounds as defined above, or of a composition as defined above, from *Mycobacterium tuberculosis*, characterized in that it comprises the following stages:

- treatment of *M. tuberculosis* bacteria with a mixture of methanol and chloroform to
- 20 obtain a chloroform/methanol extract,
- concentration of the chloroform/methanol extract followed by its partition between a chloroform phase and an aqueous phase,
  - taking of the chloroform phase and evaporation of most of the chloroform, followed by addition of acetone thereto to obtain a precipitate and a soluble acetone phase,
- 25 - taking of the soluble acetone phase followed by its concentration, and application of the concentrated soluble acetone phase on a silicic acid column irrigated with mixtures of methanol and chloroform,
- elution of a fraction from the above-mentioned silicic acid column by a mixture of chloroform and approximately 20% methanol, said fraction corresponding to a
- 30 composition as defined above,
- if necessary purification of the fraction eluted from the silicic acid column to obtain different preparations respectively containing substantially only one of the compounds as defined above.

**Brief description of the drawings****Figure 1**

Figure 1 represents the amount of IFN- $\gamma$  (in pg/ml, horizontal axis) produced by T cell clone Z4B27 in response to stimulation (vertical axis) by the culture medium (medium), by sulfoglycolipids alone (SL), by dendritic cells alone (DC) or by dendritic cells loaded with sulfoglycolipids (DC + SL)

**Figure 2**

Figure 2 represents the negative MALDI (Matrix Assisted Laser Desorption/Ionisation) mass spectrum of the purified preparation of sulfoglycolipids extracted from *M. tuberculosis* which activates the T-cell clone Z4B27. The horizontal axis represents the m/z ratio of the compounds contained in the preparation. The vertical axis represents the peak intensity as a percentage of maximum peak intensity. The major peaks are identified by their respective m/z ratio.

**Figure 3**

Figure 3 represents the 1-D  $^1\text{H}$  NMR (Nuclear Magnetic Resonance) spectrum of the purified preparation of sulfoglycolipids extracted from *M. tuberculosis* which activates the T-cell clone Z4B27. The vertical axis represents the intensity of resonance and the horizontal axis the chemical shifts in ppm (parts per million). A close-up of the spectrum between 4.7 and 5.4 ppm is inserted in the left part of the spectrum. The peak designed as  $\text{CDCl}_3$  corresponds the solvent.

**Figure 4**

Figure 4 represents a diagram showing the evolution of the number of *M. tuberculosis* CFUs (colony forming units) infecting dendritic cells ( $\times 10^{-6}$ , vertical axis) in response to the addition of increasing amounts of sulfoglycolipid specific T cell clones, represented as T cells:dendritic cells ratios on the right of the figure, between day 1 and day 5 of the experiment (horizontal axis).

**Example 1****Generation of T cell clones specific for *Mycobacterium tuberculosis* glycolipids**1. Preparation of dendritic cells

5 Immature dendritic cells (DC) were prepared from peripheral blood of healthy donors. Plastic-adherent cells were cultured in RPMI-1640 medium containing 10% FCS (foetal calf serum), 50 ng/ml recombinant human GM-CSF, 1000 U/ml recombinant human IL-4, and were used after 5 days. Before each experiment the percentage of dendritic cells was monitored by immunofluorescence analysis using mAbs specific for CD1b (WM-25, 10 Immunokontakt, Lugano, Switzerland), CD1a (OKT6) and CD1c (L161) (Instrumentation Laboratory, Schlieren, Switzerland) and was always >90%. For staining, cells were suspended in PBS containing 1% BSA and 0.04% NaN<sub>3</sub> and incubated with the primary mAbs (10 µg/ml) for 40 min, washed twice, and then further incubated with FITC-conjugated goat anti-mouse Ig for another 40 min at 4°C. After washing, cells were 15 analyzed on a FACScan flow cytometer (Becton Dickinson).

2. Generation of glycolipid-specific T cell lines

Mycobacterial glycolipids were extracted from *Mycobacterium tuberculosis* cell wall. Killed cells were treated by a mixture of chloroform and methanol, 1/1, v/v and 20 filtered, giving rise to delipidated cells and a supernatant containing cell wall glycolipids. The cells were extracted four times in the same way to yield a *M. tuberculosis* glycolipid extract.

T cell lines were established by culturing freshly isolated peripheral blood mononuclear cells (PBMC) with autologous DCs. DCs were incubated for 2 h with the 25 above mentioned glycolipids (20 µg/ml) before addition of PBMCs. After 3 weeks, growing T cells were restimulated with heterologous DCs and the same preparation of glycolipids. An identical restimulation was performed after additional 3 weeks, cells were then tested for their antigen specificity.

3. Generation of glycolipid-specific T cell clones

30 T cells from glycolipid-specific T cell lines were cloned by limiting dilution in Terasaki plates. Cloning was performed using RPMI-1640 medium added with 5% human AB serum (Swiss Red Cross, Bern), 100 U/ml recombinant human IL-2, 1% PHA (Wellcome), 2mM L-Glutamine (Gibco, 21051-024), 1mM Na Pyruvate (Gibco, 11840-



048), 1% Non-essential Aminoacids (Gibco, 11140-035), and 100 µg/ml Kanamycin (Gibco, 15160-021). Twelve days after plating, wells containing growing cells were scored and the plating efficiency was calculated according to Poisson's distribution. Cells were transferred into 96 wells plates and further expanded for one week before screening for their glycolipid specificity. The glycolipid specificity of T cell clones was detected by measuring the IFN-γ released in the supernatant 48 hr after stimulation with dendritic cells and glycolipids, using the human IFN-γ ELISA kit purchased from BD Pharmingen. The assay was performed using the protocol suggested by the dealer. Glycolipid-specific clones, such as Z4B27 (**Figure 1**), were further expanded and characterized.

#### 4. Characterization of glycolipid-specific T cell clones

DC ( $4 \times 10^4$ /well in triplicate), in RPMI-1640 medium containing 10% FCS, were preincubated for 2 h at 37°C with glycolipid antigen (1-50 µg/ml) before addition of T cells ( $6 \times 10^4$ /well). After 24-36 h of cultivation, TNF-α, IFN-γ and IL-4 released into culture supernatants were assayed by ELISA using commercial kits (Instrumentation Laboratory, Schlieren, Switzerland). C1R cells ( $6 \times 10^4$ /well in triplicate) transfected with CD1a, b, c, d or mock transfected were used in some assays.

Inhibition of T cell activation was performed by adding different doses of purified anti-CD3ε TR66 mAb Fab fragments or purified anti-CD1b WM-25 mAbs together with glycolipid-pulsed APC. After 36 h, supernatants were harvested and tested in ELISA for the presence of TNF-α, IFN-γ and IL-4. Two of the glycolipid-specific T cell clones tested, Z4B26 and Z4B27, were found to be TCR αβ<sup>+</sup>, CD8<sup>+</sup> and were restricted by CD1b. Clone Z4B27 was chosen in order to characterize the glycolipid antigens responsible for its activation.


#### Example 2

##### **Isolation and characterization of sulfoglycolipid antigens of *Mycobacterium tuberculosis* activating T cell clones**


The specific antigens responsible for the activation of the Z4B27 T cell clone were searched for.

The above mentioned mycobacterial extract was concentrated and partitioned between water and chloroform. The chloroform phase contained most of the envelope lipids

and glycolipids as well as the sulfoglycolipids. It was evaporated, and the residue was dissolved in the minimum of chloroform, then acetone was added and the mixture was kept overnight at 4°C. A precipitate was observed and by centrifugation at 4°C for 15 min (3000 x g) an "acetone-insoluble" phase and an "acetone-soluble" phase were obtained. Most of the sulfoglycolipids were found in the "acetone soluble" phase together with other lipids. The sulfoglycolipids were characterized by their behaviour on silica gel thin layer chromatography using chloroform/methanol, 9/1, v/v as migration solvent and were visualized with orcinol staining. In addition, their presence in the "acetone-soluble" phase was unambiguously established from MALDI-Time of Flight-mass spectrometry analysis (MALDI-*Tof*-MS) in negative mode. From the mass spectrum, recorded from 700 to 5000 mass units, mainly three families of sulfoglycolipids were characterized differing by their acylation degree and the fatty acyl appendage structures. The low mass range was mainly dominated by  $\alpha$ - $\alpha$ -D-trehalose-2'-sulfate (A) containing two fatty acyl appendages including one hydroxyphthioceranoic acid residue (C) and either one palmitic (HOOC-(CH<sub>2</sub>)<sub>14</sub>-CH<sub>3</sub>) or stearic acid (HOOC-(CH<sub>2</sub>)<sub>16</sub>-CH<sub>3</sub>) residue. Beside this sulfoglycolipid, other acyl-forms were observed containing one and two additional hydroxyphthioceranoic acids corresponding to the two other sulfoglycolipids families noticed above.



Trehalose-2'-sulfate  
A



Hydroxyphthioceranoic acid  
C

The "acetone-soluble" phase was then first fractionated on silicic acid column irrigated by chloroform, and chloroform containing 10, 20 and 30 % of methanol. The bioactivity, *i.e.* the capacity to activate T cell clone Z4B27, was mainly restricted to the fraction eluted with a mixture of chloroform containing 20% of methanol.

MALDI-*Tof*-MS analysis showed that this fraction was composed by  $\alpha$ - $\alpha$ -D-trehalose-2'-sulfate containing two fatty acyl appendages including hydroxyphthioceranoic acid residue with different chain lengths and either one palmitic or one stearic acid residue. **Figure 2** shows the MALDI-*Tof* spectrum recorded in negative mode using HABA [2-(4-hydroxyphenylazo)-benzoic acid] as matrix. The peaks were assigned to deprotonated

molecular ions (M-H)<sup>-</sup> thus allowing the characterization of the different molecular species summarized in Table 1.

Mass (m/z)	trehalose-2'-sulfate substituents
1039	Palmitic acid and hydroxyphthioceranoic acid (n=2, m=14)
1067	Stearic acid and hydroxyphthioceranoic acid (n=2, m=14), or palmitic acid and hydroxyphthioceranoic acid (n=2, m=16)
1123	Palmitic acid and hydroxyphthioceranoic acid (n=4, m=14)
1151	Stearic acid and hydroxyphthioceranoic acid (n=4, m=14) or palmitic acid and hydroxyphthioceranoic acid (n=4, m=16)
1165	Stearic acid and hydroxyphthioceranoic acid (n=5 m=16)
1179	Stearic acid and hydroxyphthioceranoic acid (n=4 m=16)
1193	Stearic acid and hydroxyphthioceranoic acid (n=5 m=14), or palmitic acid and hydroxyphthioceranoic acid (n=5 m=16)
1207	Palmitic acid and hydroxyphthioceranoic acid (n=6 m=14)
1235	Stearic acid and hydroxyphthioceranoic acid (n=6 m=14), or palmitic acid and hydroxyphthioceranoic acid (n=6 m=16)
1249	Palmitic acid and hydroxyphthioceranoic acid (n=7 m=14)
1263	Stearic acid and hydroxyphthioceranoic acid (n=6 m=16)
1277	Stearic acid and hydroxyphthioceranoic acid (n=7 m=14), or palmitic acid and hydroxyphthioceranoic acid (n=7 m=16)
1291	Palmitic acid and hydroxyphthioceranoic acid (n=8 m=14)
1305	Stearic acid and hydroxyphthioceranoic acid (n=7 m=16)
1319	Stearic acid and hydroxyphthioceranoic acid (n=8 m=14), or palmitic acid and hydroxyphthioceranoic acid (n=8 m=16)
1333	Palmitic acid and hydroxyphthioceranoic acid (n=9 m=14)
1361	Stearic acid and hydroxyphthioceranoic acid (n=9 m=14), or palmitic acid and hydroxyphthioceranoic acid (n=9 m=16)

Table I

5


The desulfatation of the sulfoglycolipid antigens was performed and the bioactivity of the resulting glycolipids was investigated. The sulfoglycolipids (1mg) dissolved in 1 ml of methanol were mixed with 50 mM of HCl at room temperature during 16 h. To the reaction mixture 3 ml of chloroform, 0.5 ml of methanol and 1 ml of 0.2% sodium acetate were added. The lower phase was washed with 2 x 2ml of chloroform/methanol/water 3/48/47, v/v dried and tested on silica gel high performance thin layer chromatography

10

plates. The glycolipids were visualized by orcinol staining and their migration using chloroform /methanol 9/1 as migration solvent was in agreement with the loss of the sulfate group. The desulfatation abrogated the capacity of the resulting glycolipid to activate the T cell clone Z4B27, revealing that sulfoglycolipids were the antigens which stimulate the T cell clones.

Finally, the fraction containing the diacylated  $\alpha$ - $\alpha$ -D-trehalose-2'-sulfate antigens was applied on a C18 Sep-Pak cartridge which was successively irrigated with methanol/water 9/1, methanol and methanol/chloroform, 1/1, v/v. Using the bioassay, the bioactivity was restricted to the fractions eluted with methanol and methanol/chloroform, 1/1, v/v. These fractions analyzed by MALDI-ToF-MS in negative mode showed mass spectra allowing to assign the activity to the structure I:  $\alpha$ - $\alpha$ -D-trehalose-2'-sulfate containing two fatty acyl appendages including one hydroxyphthioceranoic acid residue with different chain lengths and either one palmitic or one stearic acid residue.

From MALDI MS/MS experiments in positive mode, it was found that the two fatty acid residues were located on the same glucose unit (unit I) while the sulphate group was born by the other glucose moiety (unit II) composing the trehalose (see formula D). These data were supported by one and two dimensional  $^1\text{H}$  NMR experiments. **Figure 3** shows the one dimensional  $^1\text{H}$  spectrum. In the anomeric zone, four signals were observed namely I<sub>1</sub>, II<sub>1</sub>, II<sub>2</sub> and II<sub>3</sub>. The resonances I<sub>1</sub> and II<sub>1</sub> typified the two anomeric protons of the  $\alpha$ - $\alpha$ -trehalose core, and the resonances II<sub>2</sub> and II<sub>3</sub> were assigned to the H2 and H3 of the glucose moiety II, respectively. The downfield shifts of the H2 and H3 protons indicated that the fatty acyl appendages (hydroxyphthioceranoic acid and palmitic or stearic acids) were located on C2 and C3 of unit II. In addition, from the comparative analysis of the proton chemical shifts of the native sulfoglycolipid and its peracetylated derivative, the sulphate residue was located on the C2' of the glucose I moiety.



R1 and R2: fatty acyl appendages  
**D**

**Example 3*****Ex vivo* assay of *Mycobacterium tuberculosis* sulfoglycolipids**

To define the immunogenicity of sulfoglycolipids-antigens, IFN- $\gamma$  release was measured after stimulation with the purified sulfoglycolipids.  $2 \times 10^5$  PBMC per/well were incubated for 4 days in the presence of GM-CSF (500 U/ml) and IL-4 (5 ng/ml). Autologous effector T-cells were incubated in 10% human serum during this time. The sulfoglycolipids (10  $\mu$ g/ml) were added to the irradiated, CD1-expressing antigen-presenting cells. Finally, effector cells were added ( $2 \times 10^5$ /well) and IFN- $\gamma$  release was measured by ELISA in the supernatants after 18 hours. The IFN- $\gamma$  ELISA was performed in 96-well immunosorbent plates, which were coated with an IFN- $\gamma$  capture antibody (2  $\mu$ g/ml) overnight. Non-specific binding sites were blocked with PBS containing 1% bovine serum albumin. The supernatants were diluted 1:1 and added in a final volume of 100  $\mu$ l. Plates were incubated at room temperature for 2 hours and removed by thorough washing (3-4 times). Finally, a biotinylated anti-IFN- $\gamma$  antibody was added for 1 hour (2  $\mu$ g/ml). For detection of immunoreactive IFN- $\gamma$ , horseradish-peroxidase was added for 30 min. Finally, a chromogenic substrate (TMB, Endogen, MA, USA) was added. After 20 min. incubation the reaction was stopped by the addition of sulfuric acid (2%). The intensity of the staining was determined photometrically at a wavelength of 480 nm. To estimate the concentration of cytokine in the supernatants, an IFN- $\gamma$  standard with a known concentration was included in all tests. 82 PPD<sup>+</sup> donors (positive to the tuberculin test) and 54 PPD<sup>-</sup> donors (negative to the tuberculin test) were recruited and the response to the sulfoglycolipids was measured. Of the 82 PPD<sup>+</sup> donors 46 (56%) produced IFN- $\gamma$  (range 72 to 798 pg/ml, sensitivity of the ELISA test: 15 pg/ml), as compared to only 4 control patients (7%).


To characterize the function of T cell clones, which recognize sulfoglycolipids, the expression of antibacterial effector molecules was measured and the antibacterial activity of dendritic cells (DC) infected with virulent *M. tuberculosis* was determined. To detect granulysin, sulfoglycolipids-reactive T cell clones were permeabilised using 0.5% saponin and a polyclonal rabbit serum directed against granulysin was added. Staining was visualized using a FITC-conjugated secondary antibody directed against rabbit immunoglobulins. The number of positive cells was quantitated by analyzing cells in a flow cytometer.

For measuring the killing of *M. tuberculosis*, DCs were generated from peripheral blood monocytes by treatment with GM-CSF and IL-4. The cells were then infected with a virulent strain of *M. tuberculosis* (H37Rv) at a multiplicity of infection of 1. Non-phagocytosed bacteria were removed by thorough washing and then T-cells were added in increasing amounts as indicated in **Figure 4**. The number of surviving bacteria was determined by plating cell lysates after 5 days of coincubation and counting the number of colonies grown after three weeks. Thus, it has been shown that T-cells specific for sulfoglycolipids recognize cells infected with live mycobacteria and - most importantly - kill the pathogen. Since sulfoglycolipids-responsive cells express granulysin, the secretion of this antibacterial molecule is most likely responsible for the killing of the pathogen. Therefore, sulfoglycolipids are presented on the surface of human host cells for mycobacteria recognition and killing.

Hence, a biochemically distinct and well characterized mycobacterial lipid antigen that is predominantly recognized by PPD<sup>+</sup> donors, but not by naïve controls, was identified. T-cell clones specific for sulfoglycolipids recognize DC infected with live *M. tuberculosis* bacilli and kill the pathogen possibly by the secretion of granulysin.

## CLAIMS

1. Compounds of the following general formula (I):









I

5

wherein  $R_1$  and  $R_2$  are fatty acyl groups.


10

2. Compounds according to claim 1, wherein  $R_1$  and  $R_2$  independently from each other represent a fatty acyl group containing from 16 to 60 carbon atoms, and more particularly wherein  $R_1$  and  $R_2$  are selected from the group comprising:




wherein  $m$  is 14 or 16 and  $n$  is an integer from 2 to 10,

22



wherein m is 14 or 16 and n is an integer from 2 to 10,

3. Compounds according to claim 2, wherein R<sub>1</sub> and R<sub>2</sub> are selected from the group comprising palmitic acyl and stearic acyl, namely compounds of following formulae:




5

4. Compounds according to claim 2, wherein at least one of R<sub>1</sub> and R<sub>2</sub> represents a hydroxyphthioceranoic acyl group.
5. Compounds according to claim 4, wherein R<sub>1</sub> or R<sub>2</sub> represents a hydroxyphthioceranoic acyl group.
6. Compounds according to claim 5, wherein:
- R<sub>1</sub> represents a hydroxyphthioceranoic acyl group, and R<sub>2</sub> represents a palmitic acyl group or a stearic acyl group, namely compounds of following formula (II):


15



**II**

wherein p is 14 or 16, m is 14 or 16 and n is an integer from 2 to 10, or

- 5
- $R_2$  represents a hydroxyphthioceranoic acyl group, and  $R_1$  represents a palmitic acyl group or a stearic acyl group, namely compounds of following formula (III):

**III**

wherein p is 14 or 16, m is 14 or 16 and n is an integer from 2 to 10.

10

7. Compounds according to claim 6, of formula II, wherein:

-  $n = 2$ ,  $m = 14$  and  $p = 14$  (II.1);

-  $n = 2$ ,  $m = 14$  and  $p = 16$  (II.2);

-  $n = 2$ ,  $m = 16$  and  $p = 14$  (II.3);

-  $n = 2$ ,  $m = 16$  and  $p = 16$  (II.4);

-  $n = 3$ ,  $m = 14$  and  $p = 14$  (II.5);

-  $n = 3$ ,  $m = 14$  and  $p = 16$  (II.6);

-  $n = 3$ ,  $m = 16$  and  $p = 14$  (II.7);

-  $n = 3$ ,  $m = 16$  and  $p = 16$  (II.8);

-  $n = 4$ ,  $m = 14$  and  $p = 14$  (II.9);

-  $n = 4$ ,  $m = 14$  and  $p = 16$  (II.10);

15

20

- $n = 4, m = 16$  and  $p = 14$  (II.11);
- $n = 4, m = 16$  and  $p = 16$  (II.12);
  
- $n = 5, m = 14$  and  $p = 14$  (II.13);
- 5 -  $n = 5, m = 14$  and  $p = 16$  (II.14);
- $n = 5, m = 16$  and  $p = 14$  (II.15);
- $n = 5, m = 16$  and  $p = 16$  (II.16);
  
- $n = 6, m = 14$  and  $p = 14$  (II.17);
- 10 -  $n = 6, m = 14$  and  $p = 16$  (II.18);
- $n = 6, m = 16$  and  $p = 14$  (II.19);
- $n = 6, m = 16$  and  $p = 16$  (II.20);
  
- $n = 7, m = 14$  and  $p = 14$  (II.21);
- 15 -  $n = 7, m = 14$  and  $p = 16$  (II.22);
- $n = 7, m = 16$  and  $p = 14$  (II.23);
- $n = 7, m = 16$  and  $p = 16$  (II.24);
  
- $n = 8, m = 14$  and  $p = 14$  (II.25);
- 20 -  $n = 8, m = 14$  and  $p = 16$  (II.26);
- $n = 8, m = 16$  and  $p = 14$  (II.27);
- $n = 8, m = 16$  and  $p = 16$  (II.28);
  
- $n = 9, m = 14$  and  $p = 14$  (II.29);
- 25 -  $n = 9, m = 14$  and  $p = 16$  (II.30);
- $n = 9, m = 16$  and  $p = 14$  (II.31);
- $n = 9, m = 16$  and  $p = 16$  (II.32);
  
- $n = 10, m = 14$  and  $p = 14$  (II.33);
- 30 -  $n = 10, m = 14$  and  $p = 16$  (II.34);
- $n = 10, m = 16$  and  $p = 14$  (II.35);
- $n = 10, m = 16$  and  $p = 16$  (II.36);

or of formula III, wherein:

5

- $n = 2, m = 14$  and  $p = 14$  (III.1) ;
- $n = 2, m = 14$  and  $p = 16$  (III.2) ;
- $n = 2, m = 16$  and  $p = 14$  (III.3) ;
- $n = 2, m = 16$  and  $p = 16$  (III.4) ;

10

- $n = 3, m = 14$  and  $p = 14$  (III.5) ;
- $n = 3, m = 14$  and  $p = 16$  (III.6) ;
- $n = 3, m = 16$  and  $p = 14$  (III.7) ;
- $n = 3, m = 16$  and  $p = 16$  (III.8) ;

15

- $n = 4, m = 14$  and  $p = 14$  (III.9) ;
- $n = 4, m = 14$  and  $p = 16$  (III.10) ;
- $n = 4, m = 16$  and  $p = 14$  (III.11) ;
- $n = 4, m = 16$  and  $p = 16$  (III.12) ;

20

- $n = 5, m = 14$  and  $p = 14$  (III.13) ;
- $n = 5, m = 14$  and  $p = 16$  (III.14) ;
- $n = 5, m = 16$  and  $p = 14$  (III.15) ;
- $n = 5, m = 16$  and  $p = 16$  (III.16) ;

25

- $n = 6, m = 14$  and  $p = 14$  (III.17) ;
- $n = 6, m = 14$  and  $p = 16$  (III.18) ;
- $n = 6, m = 16$  and  $p = 14$  (III.19) ;
- $n = 6, m = 16$  and  $p = 16$  (III.20) ;

30


- $n = 7, m = 14$  and  $p = 14$  (III.21) ;
- $n = 7, m = 14$  and  $p = 16$  (III.22) ;
- $n = 7, m = 16$  and  $p = 14$  (III.23) ;
- $n = 7, m = 16$  and  $p = 16$  (III.24) ;

- $n = 8, m = 14$  and  $p = 14$  (III.25) ;
- $n = 8, m = 14$  and  $p = 16$  (III.26) ;
- $n = 8, m = 16$  and  $p = 14$  (III.27) ;
- $n = 8, m = 16$  and  $p = 16$  (III.28) ;


- $n = 9, m = 14$  and  $p = 14$  (III.29);
- $n = 9, m = 14$  and  $p = 16$  (III.30);
- $n = 9, m = 16$  and  $p = 14$  (III.31);
- $n = 9, m = 16$  and  $p = 16$  (III.32);

- $n = 10, m = 14$  and  $p = 14$  (III.33);
- $n = 10, m = 14$  and  $p = 16$  (III.34);
- $n = 10, m = 16$  and  $p = 14$  (III.35);
- $n = 10, m = 16$  and  $p = 16$  (III.36);


8. Compounds according to claim 7, of following formulae:




III.21




II.21




III.22



II.22



III.23



II.23

9. A composition comprising at least two different compounds of formula I such as defined in any of claims 1 to 8.

5 10. A composition according to claim 9, characterized in that it comprises a mixture of compounds selected from the compounds as defined in any of claims 6 to 8.

10 11. A composition according to claim 9 or 10, wherein compounds selected from the compounds of claim 8 represent from about 20% to about 100%, more particularly about 30%, of the total amount of compounds of formula I of said composition.

12. A pharmaceutical composition comprising at least one compound according to any of claims 1 to 8, or a composition according to any of claims 9 to 11, in association with a pharmaceutically acceptable vehicle.

15 13. A pharmaceutical composition according to claim 12, characterized in that it is presented in a form intended for administration by oral or injectable route.

20 14. A pharmaceutical composition according to claim 12 or 13, characterized in that it comprises one or more other products useful for the treatment or the prophylaxis of tuberculosis, such as BCG or mycobacterial proteins.

15. Products comprising:

- 25 - at least one compound according to any of claims 1 to 8,  
- and at least one other product useful for the treatment or the prophylaxis of tuberculosis, such as BCG or mycobacterial proteins,  
as a combined preparation for simultaneous, separate or sequential use in the treatment or the prophylaxis of tuberculosis.

30 16. Use of at least one compound according to any one of claims 1 to 8, or of a composition according to any of claims 9 to 11, for the preparation of a medicament, notably a vaccine, intended for the treatment or the prophylaxis of tuberculosis.

17. Use of at least one compound according to any one of claims 1 to 8, or of a composition according to any of claims 9 to 11, as an immune reaction activator, and more particularly an inflammatory reaction activator.

5 18. Use of at least one compound according to any one of claims 1 to 8, or of a composition according to any of claims 9 to 11, to induce the activation of T lymphocytes.

10 19. Use of at least one compound according to any one of claims 1 to 8, or of a composition according to any of claims 9 to 11, to induce the production of IFN- $\gamma$ , TNF- $\alpha$ , IL-4 or granulysin.

20. A process for generating T cell clones, characterized in that it comprises the following stages:

- 15
- incubating antigen presenting cells (APCs), notably dendritic cells, with a *Mycobacterium tuberculosis* envelope preparation substantially devoid of proteins, to obtain non-protein envelope antigen loaded APCs,
  - contacting peripheral blood mononuclear cells with the envelope antigen loaded APCs to obtain proliferating T cells,
  - 20 - cloning proliferating T cells by limiting dilution and selecting the clones releasing a molecule selected from the group comprising IFN- $\gamma$ , TNF- $\alpha$ , granulysin or IL-4 when contacted by envelope antigen loaded APCs to obtain T cell clones.

25 21. T cell clones such as obtained by the process according to claim 20.

22. A process for screening products, such as sulfoglycolipids extracted from *Mycobacterium tuberculosis*, characterised in that it comprises the following stages:

- 30
- contacting dendritic cells loaded with the product to screen, notably sulfoglycolipids extracted from *Mycobacterium tuberculosis*, with T cell clones according to claim 21,
  - detecting a molecule selected from the group comprising IFN- $\gamma$ , TNF- $\alpha$ , granulysin or IL-4, released by the T cell clones.

23. A process for the extraction of compounds according to any of claims 1 to 8, or of a composition according to any of claims 9 to 11, from *Mycobacterium tuberculosis*, characterized in that it comprises the following stages:

- treatment of *M. tuberculosis* bacteria with a mixture of methanol and chloroform to obtain a chloroform/methanol extract,
- concentration of the chloroform/methanol extract followed by its partition between a chloroform phase and an aqueous phase,
- taking of the chloroform phase and evaporation of most of the chloroform, followed by addition of acetone thereto to obtain a precipitate and a soluble acetone phase,
- taking of the soluble acetone phase followed by its concentration, and application of the concentrated soluble acetone phase on a silicic acid column irrigated with mixtures of methanol and chloroform,
- elution of a fraction from the above-mentioned silicic acid column by a mixture of chloroform and approximately 20% methanol, said fraction corresponding to a composition according to any of claims 9 to 11,
- if necessary purification of the fraction eluted from the silicic acid column to obtain different preparations respectively containing substantially only one compound according to any of claims 1 to 8.



1/4




Figure 1

JCO9 Rec'd PCT/PTO 18 OCT 2009

THIS PAGE BLANK (USPTO)




Figure 2

JCO9 Rec'd PCT/PTO 18 OCT 2009

THIS PAGE BLANK (USPTO)




Figure 3

JCO9 Rec'd PCT/PTO 18 OCT 2009

**THIS PAGE BLANK (USPTO)**




Figure 4

JC09 Rec'd PCT/PTO 18 OCT 2005

**THIS PAGE BLANK (USPTO)**



# INTERNATIONAL SEARCH REPORT

International Application No

PCT/EP2004/003830

## A. CLASSIFICATION OF SUBJECT MATTER

IPC 7 C07H11/00 C07H13/06 C07H17/04 A61K31/7024 A61P31/06

According to International Patent Classification (IPC) or to both national classification and IPC

## B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 7 C07H A61K A61P

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

EPO-Internal, WPI Data, CHEM ABS Data

## C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	I. VERGNE, M. DAFFÉ: "Interaction of mycobacterial glycolipids with host cells" FRONTIERS IN BIOSCIENCE, vol. 3, 1998, pages 865-876, XP008023822 cited in the application abstract, introduction figure 1b section 3.1.2 -----	1, 14

☐

Further documents are listed in the continuation of box C.

☐

Patent family members are listed in annex.

### \* Special categories of cited documents :

- \*A\* document defining the general state of the art which is not considered to be of particular relevance
- \*E\* earlier document but published on or after the international filing date
- \*L\* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- \*O\* document referring to an oral disclosure, use, exhibition or other means
- \*P\* document published prior to the international filing date but later than the priority date claimed

\*T\* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

\*X\* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

\*Y\* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

\*G\* document member of the same patent family

Date of the actual completion of the international search

18 August 2004

Date of mailing of the international search report

30/08/2004

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2  
NL - 2280 HV Rijswijk  
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,  
Fax: (+31-70) 340-3016

Authorized officer

de Nooy, A

**THIS PAGE BLANK (USPTO)**

This Page is inserted by IFW Indexing and Scanning  
Operations and is not part of the Official Record

## **BEST AVAILABLE IMAGES**

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

- ☒ BLACK BORDERS
- ☒ IMAGE CUT OFF AT TOP, BOTTOM OR SIDES
- ☒ FADED TEXT OR DRAWING
- ☐ BLURED OR ILLEGIBLE TEXT OR DRAWING
- ☐ SKEWED/SLANTED IMAGES
- ☒ COLORED OR BLACK AND WHITE PHOTOGRAPHS
- ☐ GRAY SCALE DOCUMENTS
- ☐ LINES OR MARKS ON ORIGINAL DOCUMENT
- ☐ REPERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY
- ☐ OTHER: \_\_\_\_\_

**IMAGES ARE BEST AVAILABLE COPY.**

**As rescanning documents *will not* correct images problems checked, please do not report the problems to the IFW Image Problem Mailbox**

